Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies.
Excess weight
Immunotherapy
advanced cancer
anti-PD-1
excess weight
immune-related adverse events
immune-related adverse-events
nivolumab
obesity
overweight
pembrolizumab
predictive Factor
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
11
2019
revised:
02
02
2020
accepted:
29
02
2020
entrez:
5
5
2020
pubmed:
5
5
2020
medline:
5
5
2020
Statut:
epublish
Résumé
Immunotherapy is an effective treatment in advanced cancer, although predictors of response are limited. We studied whether excess weight influences the efficacy outcomes of immunotherapy. We have also evaluated the combined prognostic effect of excess weight and immune-related adverse events (irAEs). Efficacy of anti-PD-1 treatment was evaluated with both objective radiological response (ORR) rate and progression-free survival (PFS), and toxicity with irAEs. We studied the association between excess weight and ORR, PFS or irAEs. 132 patients diagnosed with advanced cancer were included. Median body mass index (BMI) was 24.9 kg/m2. 64 patients had normal weight (BMI<25 kg/m2), and 64 patients had excess weight (BMI≥25 kg/m2). Four patients had underweight and were excluded from further analysis. ORR was achieved in 50 patients (38.0%), median PFS was 6 months. 44 patients developed irAEs (33.3%). ORR was higher in excess weight patients than in patients with normal weight (51.6% vs 25.0%; OR 3.45,
Identifiants
pubmed: 32363123
doi: 10.1080/2162402X.2020.1751548
pii: 1751548
pmc: PMC7185216
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Immune Checkpoint Inhibitors
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1751548Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
JAMA. 2013 Jan 2;309(1):71-82
pubmed: 23280227
Nat Rev Cancer. 2004 Aug;4(8):579-91
pubmed: 15286738
J Thorac Oncol. 2017 Oct;12(10):1478-1488
pubmed: 28757418
Clin Cancer Res. 2018 Dec 1;24(23):5841-5849
pubmed: 29891725
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
Nat Med. 2019 Jan;25(1):141-151
pubmed: 30420753
J Surg Res. 2011 Sep;170(1):e75-83
pubmed: 21704331
Lancet Oncol. 2018 Mar;19(3):310-322
pubmed: 29449192
N Engl J Med. 2003 Apr 24;348(17):1625-38
pubmed: 12711737
Lancet. 2009 Mar 28;373(9669):1083-96
pubmed: 19299006
JAMA. 2005 Apr 20;293(15):1861-7
pubmed: 15840860
Eur J Cancer. 2019 Mar;109:21-27
pubmed: 30682533
JAMA. 2019 Apr 2;321(13):1247-1248
pubmed: 30882850
Lancet. 2014 Aug 30;384(9945):755-65
pubmed: 25129328
Lancet Oncol. 2016 Sep;17(9):1283-94
pubmed: 27451390
Lung Cancer. 2017 Feb;104:52-57
pubmed: 28213000
Lancet Oncol. 2010 Aug;11(8):741-52
pubmed: 20594911
J Clin Oncol. 2019 Mar 20;37(9):693-702
pubmed: 30726175
Int J Obes (Lond). 2015 Jun;39(6):877-83
pubmed: 25697667
PLoS One. 2018 Oct 1;13(10):e0204729
pubmed: 30273398
J Clin Oncol. 2016 Oct 20;34(30):3655-3663
pubmed: 27601543
Trends Immunol. 2016 Jun;37(6):354-363
pubmed: 27105824
Eur J Cancer. 2018 Jul;98:1-9
pubmed: 29807237
JAMA Netw Open. 2018 Nov 2;1(7):e184587
pubmed: 30646366
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
Nat Rev Clin Oncol. 2013 Sep;10(9):519-33
pubmed: 23856746
J Thorac Oncol. 2013 Sep;8(9):1121-7
pubmed: 23887169